Alteplase ThromboLysis for Acute Noninterventional Therapy in Ischemic Stroke "ATLANTIS"

Completed

Phase 3 Results

Summary of Purpose

To assess the efficacy and safety of 0.9 mg/kg intravenous rtPA (Alteplase) vs placebo in acute ischemic stroke patients treated within 3 to 5 hours of stroke onset.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 21 September 2000.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • Genentech, Inc.

Trial Design

Placebo-controlled, double-blind, randomized study of 613 patients at 140 centers.

Contacts

Not available